SOURCE: Protherics PLC

November 20, 2007 02:06 ET

Protherics Announces Interim Results For Six Months Ended 30 September 2007

Cheshire, UK--(Marketwire - November 20, 2007) -

                  FOR SIX MONTHS ENDED 30 SEPTEMBER 2007

              Strong progress in broad late-stage pipeline
         Sharp rise in revenues, gross profits and cash position

London, UK, Brentwood, TN, 20 November 2007 - Protherics PLC ("Protherics" or the "Company"), the biopharmaceutical company focused on critical care and cancer, today announces its unaudited interim results for the six months ended 30 September 2007.

Operational Highlights

*  CroFabTM and DigiFabTM: stronger than expected market sales helped
   drive 31% revenue growth over the corresponding six month period 
   in 2006

*  CytoFabTM:

   -   AstraZeneca expected to start its expanded CytoFabTM phase 2
       programme in Q4 2007
   -   excellent potency data from large-scale CytoFabTM manufacturing
       process allows deferral of major manufacturing investment until
       start of phase 3 study
   -   milestone payments schedule supports Protherics' manufacturing

*  Digoxin Immune Fab: recruitment in phase 2b "DEEP" study in severe
   pre-eclampsia completed ahead of schedule and on track to report in
   Q2 2008 (see separate release)
*  VoraxazeTM:

   -   revenues significantly ahead of expectations due to cost 
       recovery programme in the US
   -   work on track to support resubmission of marketing application
       in the US and meeting requested with EMEA

*  OncoGelTM:

   -   phase 2b study initiated in oesophageal cancer following 
       encouraging phase 2a results
   -   independent safety review ongoing following treatment of the 
       first cohort of three patients in phase 1/2 primary brain cancer 
       (glioblastoma multiforme) study

*  ProlarixTM: maximum tolerated dose determined and phase 2 to start in
   the first half of 2008
*  AcadraTM (acadesine): proof of concept phase 1/2 study initiated in 
   the EU 
*  CoVaccine HT was out-licensed to Nobilon B.V. (Organon BioSciences /
   Schering Plough) for use in flu vaccines and ReGelTM was out-licensed to
   Myungmoon Pharm. Co. Ltd., a South Korean pharmaceutical company, for
   use in arthritis indications

Financial Highlights

*   Revenues increased by 31% to GBP14.8m (2006: GBP11.3m) with 
    significant growth in CroFabTM and VoraxazeTM
*   Gross profit up 32% to GBP8.2m (2006: GBP6.2m) delivering gross 
    margins of 55.4% (2006: 55.2%) on improved volumes
*   R&D increased to GBP8.6m (2006: GBP7.1m) with investment in 
    CytoFabTM, VoraxazeTM  as well as the new products acquired during
    the previous financial year
*   G&A expenses increased to GBP6.7m (2006: GBP4.1m) and includes 
    additional costs from the MacroMed acquisition
*   Loss before tax of GBP6.1m (2006: GBP4.7m) reflects improved trading
    performance offset by higher R&D and G&A
*   Net cash increase of GBP6.9m (2006: GBP7.5m decrease) due to receipt
    of GBP10m milestone payment from AstraZeneca in April 2007
*   Strong cash position of GBP46.9m (2006: GBP17.9m) following fund 
    raising of GBP38.4m in January 2007 and the GBP10m milestone payment
    from AstraZeneca.

Commenting on the results, Stuart Wallis, Chairman, said:

"Protherics delivered good progress in the first half with its broad clinical pipeline and has today announced that the phase 2 DEEP study in pre-eclampsia has completed recruitment. We have also generated a significant increase in revenues and gross profits due to the strong market performance of CroFab and DigiFab. With CytoFab, the scaled up manufacturing process has produced a highly potent product, allowing us to defer much of our investment in manufacturing until the start of phase 3 with no anticipated impact on product launch. AstraZeneca is expected to start its CytoFab phase 2 programme imminently.

"The rest of our development pipeline continues to advance as planned, with six phase 2 programmes expected to be on-going in 2008, including the phase 2b severe pre-eclampsia study which is on track to deliver results in the second quarter of 2008. With a diverse and developing portfolio, strong trading and a robust cash position, we are confident in Protherics' prospects."

                                   |  Ends  |

There will be an analyst meeting at 9.30am UK time on Tuesday 20 November 2007 in London at the offices of Financial Dynamics at Holborn Gate, 26 Southampton Buildings, WC2A 1PB. There will be a simultaneous conference call and webcast. For further details, please contact Mo Noonan on +44 (0)20 7269 7116. To access the webcast please visit

For further information contact:

Protherics PLC                               +44 (0) 20 7246 9950
                                             +44 (0) 7919  480510
Andrew Heath, CEO
Rolf Soderstrom, Finance Director
Nick Staples, Corporate Affairs

Protherics Inc                               +1 615 327 1027
Saul Komisar, President

Financial Dynamics
London: Ben Atwell / Lara Mott               +44 (0) 20 7831 3113
New York: Jonathan Birt / John Capodanno     +1 212 850 5600

Notes for Editors:

About Protherics

Protherics (LSE: PTI, NASDAQ: PTIL) is a leading biopharmaceutical company focused on the development, manufacture and marketing of specialised products for critical care and cancer.

Protherics has developed and manufactures two biologics for critical care which are FDA approved and currently sold in the US: CroFabTM, a pit viper antivenom and DigiFabTM, a digoxin antidote. The Company's strategy is to use the revenues generated from its marketed and out-licensed products to help fund the advancement of its broad, late stage pipeline.

Protherics has two major development opportunities in its critical care portfolio. CytoFabTM is being developed by AstraZeneca, for the treatment of severe sepsis, after a major GBP195 million licensing deal with AstraZeneca in December 2005. An additional, expanded phase 2 programme is due to start shortly. In addition, Protherics is currently undertaking a phase 2b study with Digoxin Immune Fab for the treatment of pre-eclampsia. This study is expected to report in the first half of 2008.

Protherics has a pipeline of four novel cancer products in clinical development, and intends to undertake the sales and marketing of these products in the US and or the EU. Protherics is preparing to resubmit a BLA for VoraxazeTM, an adjunct to high dose methotrexate therapy, under a rolling submission in the US starting in H1 2008.

Protherics has a strong cash position, with cash balances at 30 September 2007 of GBP46.9 million, having completed a GBP38 million equity fundraising in January 2007 and received a GBP10 million milestone payment from AstraZeneca in April 2007.

With headquarters in London, the Company has approximately 290 employees across its operations in the UK, US and Australia.

For further information visit:


This document contains forward-looking statements that involve risks and uncertainties including with respect to future growth, technology acquisitions, product sales and manufacturing, and regulatory approval of Protherics' products for marketing and distribution. Although we believe that the expectations reflected in such forward-looking statements are reasonable at this time, we can give no assurance that such expectations will prove to be correct. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors, including the market for the Company's products, the timing and receipt of regulatory approvals, the successful integration of acquired businesses and intellectual property, and other factors discussed in Protherics' Annual Report on Form 20-F and other reports filed from time to time with the U.S. Securities and Exchange Commission. We do not undertake to update any oral or written forward-looking statements that may be made by, or on behalf of, Protherics.

To view the full text of this press release, paste the following link into your web browser:

                      This information is provided by RNS
            The company news service from the London Stock Exchange